Skip to content
Sexuality – Lifestyle
Author:
DIAGONAL THERAPEUTICS, INC
Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)
July 16, 2026
Diagonal Therapeutics Expands Executive Leadership Team, Appoints Industry Veteran Jonathan Piazza as Chief Financial Officer
May 5, 2026